Compare RLX Technology Inc (RLX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs BIO-TECHNE Corp — how do they compare? RLX Technology Inc trades at $1.73 (market cap $2.10B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 5.4× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 34 Days and BIO-TECHNE Corp for 63 Days on average.
| RLX | TECH | |
|---|---|---|
Market Cap | $2.10B | $11.36B |
Volume | 1,079,706 | 5,390,331 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $72.61 |
52-Week Low | $1.68 | $43.31 |
Typical Hold Time | 34 Days | 63 Days |
Enterprise Value | $832.26M | $11.39B |
Dividend Yield | 5.81% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.73, showing no change in the latest session and recently hitting 52-week lows. The stock exhibits bearish technical signals with mixed fundamentals - revenue grew to $3.62B in 2025 with strong 21.87% net margins, but recent quarters show consistent earnings misses. Analyst coverage remains limited with a single hold rating, while cash flow trends show volatility with negative net cash flow in 2025.
RLX faces near-term headwinds from earnings underperformance and technical weakness, though valuation appears reasonable with P/E of 15.46 and P/B below 1.0. International expansion provides growth potential, but regulatory risks and margin compression require monitoring for sustained recovery.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
